Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline-Reference-Cited by-同舟云学术

Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline

Published:2018-09-18 Issue:20 Volume:61 Page:9360-9370
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lee Patrick S.¹^ORCID,Lapointe Guillaume¹,Madera Ann Marie¹,Simmons Robert L.¹,Xu Wenjian¹,Yifru Aregahegn¹,Tjandra Meiliana¹,Karur Subramanian¹,Rico Alice¹,Thompson Katherine¹,Bojkovic Jade¹,Xie Lili¹,Uehara Kyoko¹,Liu Amy¹,Shu Wei¹,Bellamacina Cornelia¹,McKenney David¹,Morris Laura¹,Tonn George R.¹,Osborne Colin¹,Benton Bret M.¹,McDowell Laura¹,Fu Jiping¹,Sweeney Zachary K.¹

Affiliation:

1. Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01287

Reference38 articles.

1. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

2. The rise of carbapenem resistance in Europe: just the tip of the iceberg?

3. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now